Show menu

Custom development


An agile & scientific CRDO platform

Seqens provides active Pharmaceutical Ingredient (API) and drug substance development services. We support emerging and large pharmaceutical customers in human and animal health with their pharmaceutical and biotechnology applications for complex, niche and small molecule programs through two main R&D locations in the regions of Boston and Paris.


Early phase development

Seqens’ Development team operates state of the art R&D facilities to handle the most complex API development challenges. With a broad range of experience and knowledge of the latest technologies in organic synthesis, our chemists establish robust and economical routes for the synthesis of API.

  • Route scouting
  • Process development
  • Process Safety
  • Analytical development
  • Preliminary ICH stability profile
  • Non-GMP  API supply for tox batches
  • FTH and API clinical supply using cGMP kilo-lab suites
  • IND document preparation & review (CMC or DMF preparation)

Special features

  • Controlled substances
  • Solid state services including polymorphism screening and salt selection
  • Multicatalysis
  • Biocatalysis 
  • Flow chemistry

Late phase development

Our R&D teams France & USA together with our Regulatory Affairs team in Ecully, France provide API cGMP services.

  • Quality by design methodology
  • Process and crystallization optimization studies
  • Fate and purge studies
  • Analytical method development and ICH validation
  • Kilo-scale, pilot scale or multi-ton scale manufacturing to support phase III or launch
  • non-GMP and GMP Raw material back integration
  • ICH stability studies

Special features

  • Cryogenic, very high pressure capabilities
  • Flow Chemistry capabilities (up to 2 MT/year)
  • Highly potent APIs down to 100 ng/m3
From discovery to commercial

Our CRDO offer

4 agile and scientific CRDO platforms, on all the API lifecycle from New Molecular Entities (NME) synthesis until Early Clinical Formulation*
Discover our new offer to empower your API


Learn more

SEQENS has extended its offer towards a comprehensive solution from Drug Substance to its early-phase formulation

–  Development of phase-appropriate oral formulations

–  Services to support your preclinical ADME studies
and first in human clinical trials (phases I and IIa)


Download our brochure

CMC  project management

Our R&D teams in France and USA, are experienced in providing API CMC (Chemistry, Manufacturing and Controls) solutions, including IND-enabling, to meet your project needs.

Know more

Learn more about our R&D capabilities

Learn more

R&D is at the heart of Seqens’ strategy. With 10 centers of excellence around the world, including more than 300 researchers, 130 of whom are PhDs, Seqens has unique capabilities to support its customers in the development of complex molecules across all markets.